IDHIFA®, the only non-cytotoxic, targeted inhibitor of the mutant IDH2 enzyme, releases the block on myeloid differentiation.
The normal IDH2 enzyme converts isocitrate to alpha-ketoglutarate (α-KG), a substrate for enzymes essential to gene expression and myeloid differentiation.1-5
Mutated IDH2 converts α-KG to 2-hydroxyglutarate (2-HG), an oncometabolite that leads to a block on myeloid differentiation and results in myeloblast proliferation.1-5
In preclinical studies, IDHIFA® blocked the conversion of α-KG to 2-HG. In patient blood samples, IDHIFA® decreased 2-HG levels and induced myeloid differentiation.6
Eligibility
Patients must meet the following criteria to enroll:
Program Benefits
Program Timing
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216